Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 30, Issue 9, 2002, Pages 619-626

  Worel, N ^a   Biener, D ^a   Kalhs, P ^a   Mitterbauer, M ^a   Keil, F ^a   Schulenburg, A ^a   Hocker P ^a   Dieckmann, K ^a   Fischer, G ^a   Rosenmayr, A ^a   Linkesch, W ^a   Hinterberger, W ^a   Lechner, K ^a   Greinix, H T ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allogeneic SCT; Long term outcome; Quality of life

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; BUSULFAN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXPERIENCE; FEMALE; FITNESS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PARENT; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL INTERACTION; STEM CELL TRANSPLANTATION; SURVIVAL TIME; SYNGENEIC STEM CELL TRANSPLANTATION; TIME; WORK CAPACITY; ALLOTRANSPLANTATION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ISOGRAFT; MIDDLE AGED; NEWBORN; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT, NEWBORN; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC; TREATMENT OUTCOME;

EID: 0036857763     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703677     Document Type: Article

References (37)

1. O'Donnell MR, Nademanee AP, Snyder DS et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987; 5: 1822-1826.
2. Gahrton G, Tura S, Ljungman P et al. Allogeneic bone marrow transplantation in multiple myeloma. New Engl J Med 1991; 325: 1267-1273.
3. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by bone marrow transplantation. Blood 1993; 82: 1954-1956.
4. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995; 332: 217-223.
5. Passweg JR, Socié G, Hinterberger W et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997; 90: 858-864.
6. de Witte T, Hermans J, Vossen J et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620-630.
7. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
8. Appelbaum FR. The influence of total dose, fractionation, dose rate, and distribution of total body irradiation on bone marrow transplantation. Semin Oncol 1993; 20 (Suppl. 4): 3-10.
9. Tutschka PJ. Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting. Bone Marrow Transplant 1993; 12 (Suppl. 1): 34-36.
10. Boeckh M, Bowden RA, Gooley T et al. Successful modification of a pp65 antigenemia based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999; 93: 1781-1782.
11. Roy V, Ochs L, Weisdorf D. Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 1997; 26: 1-15.
12. Winston DJ, Gale RP. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplant 1991; 8: 7-11.
13. Fischer GF, Faé I, Petrasek M, Moser S. A combination of two distinct in vitro amplification procedures for DNA typing of HLA-DRB and -DQB1 alleles. Vox Sang 1995; 69: 328-335.
14. Greinix HT, Volc-Platzer B, Knobler RM. Extracorporeal photochemotherapy in the treatment of severe graft-versus-host disease. Leuk Lymphoma 2000; 36: 425-434.
15. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for acute leukemia. New Engl J Med 1986; 314: 729-735.
16. Frassoni F, Labopin M, Gluckman E et al. Are patients with acute leukemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Leukemia 1994; 8: 924-928.
17. Singhal S, Powles R, Treleaven J et al. Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling. Leuk Lymphoma 1999; 34: 287-294.
18. Deeg HJ, Socié G, Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386-392.
19. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. New Engl J Med 1997; 336: 897-904.
20. Sutherland HJ, Fyles GM, Adams G et al. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant 1997; 19: 1129-1136.
21. Hjermstad MJ, Holte H, Evensen SA et al. Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant 1999; 24: 911-918.
22. Chiodi S, Spinelli S, Ravera G et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000; 110: 614-619.
23. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-843, 895-902.
24. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
25. Sullivan KM, Witherspoon RP, Storb R et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood 1988; 72: 555-561.
26. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
27. Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of life of 125 adults surviving 6-8 years after bone marrow transplantation. Soc Sci Med 1995; 40: 479-490.
28. Rabitsch W, Deviatko E, Keil F et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation 2001; 71: 1341-1343.
29. Gmeinhart B, Hinterberger W, Greinix HT et al. Anaplastic squamous cell carcinoma (SCC) in a patient with chronic cutaneous graft-versus-host disease (GVHD). Bone Marrow Transplant 1999; 11: 1197-1199.
30. Reiter E, Greinix HT, Keil F et al. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol 1999; 78: 507-513.
31. Hinterberger-Fischer M, Kier P, Kalhs P et al. Fertility, pregnancies and offspring complications after bone marrow transplantation. Bone Marrow Transplant 1991; 7: 5-9.
32. Witherspoon R, Flournoy N, Thomas ED et al. Recurrence of acute leukemia more than two years after allogeneic marrow grafting. Exp Hematol 1986; 14: 178-181.
33. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1996; 86: 2041-2050.
34. Sanders JE, Hawley J, Levy W et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87: 3045-3052.
35. Syrjala KL, Chapko MK, Vitaliano PP et al. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant 1993; 11: 319-327.
36. Andrykowski MA, Brady MJ, Greiner CB et al. 'Returning to normal' following bone marrow transplantation: outcomes, expectations and informed consent. Bone Marrow Transplant 1995; 15: 573-581.
37. Duell T, Van Lint MT, Ljungman P et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT working party on late effects and EULEP study group on late effects. European group for blood and marrow transplantation. Ann Intern Med 1997; 126: 184-192.